Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominik Wolf

Showing results (271-280 of 331) with videos related to

Pageof 34
Sort By:
Cancers|March 11, 2023
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMTLisa Pleyer, Sonja Heibl, Christoph Tinchon, et al.
Wiener Klinische Wochenschrift|February 16, 2022
SARS-CoV-2-related mortality and treatment delays for cancer patients in Austria : Findings of a multicentric nationwide studyJulia M Berger, Phillipp Wohlfarth, Oliver Königsbrügge, et al.
Translational Lung Cancer Research|December 13, 2024
Prognostic impact of targetable driver alterations in resected early-stage lung cancerAngelika Terbuch, Selma Konjic, Verena Schlintl, et al.
Leukemia|January 26, 2024
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trialHjalmar Flygt, Stina Söderlund, Johan Richter, et al.
Annals of Hematology|March 4, 2024
Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignanciesPatrick Reimann, Verena Petzer, Axel Mündlein, et al.
Hemasphere|February 21, 2022
Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid MalignanciesVerena Petzer, Normann Steiner, Olga Angelova-Unterberger, et al.
American Journal of Hematology|December 30, 2014
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2bNicole C C Them, Klaudia Bagienski, Tiina Berg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2021
Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)Nicolaus Kröger, Katja Sockel, Christine Wolschke, et al.
Cancers|May 28, 2022
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-GroupMichael Leisch, Michael Pfeilstöcker, Reinhard Stauder, et al.
Annals of the Rheumatic Diseases|August 16, 2022
Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remissionGabriele Gamerith, Finn Mildner, Peter A Merkel, et al.
Pageof 34

Showing results (271-280 of 331) with videos related to

Sort By:
Pageof 34
Cancers|March 11, 2023
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMTLisa Pleyer, Sonja Heibl, Christoph Tinchon, et al.
Wiener Klinische Wochenschrift|February 16, 2022
SARS-CoV-2-related mortality and treatment delays for cancer patients in Austria : Findings of a multicentric nationwide studyJulia M Berger, Phillipp Wohlfarth, Oliver Königsbrügge, et al.
Translational Lung Cancer Research|December 13, 2024
Prognostic impact of targetable driver alterations in resected early-stage lung cancerAngelika Terbuch, Selma Konjic, Verena Schlintl, et al.
Leukemia|January 26, 2024
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trialHjalmar Flygt, Stina Söderlund, Johan Richter, et al.
Annals of Hematology|March 4, 2024
Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignanciesPatrick Reimann, Verena Petzer, Axel Mündlein, et al.
Hemasphere|February 21, 2022
Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid MalignanciesVerena Petzer, Normann Steiner, Olga Angelova-Unterberger, et al.
American Journal of Hematology|December 30, 2014
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2bNicole C C Them, Klaudia Bagienski, Tiina Berg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2021
Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)Nicolaus Kröger, Katja Sockel, Christine Wolschke, et al.
Cancers|May 28, 2022
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-GroupMichael Leisch, Michael Pfeilstöcker, Reinhard Stauder, et al.
Annals of the Rheumatic Diseases|August 16, 2022
Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remissionGabriele Gamerith, Finn Mildner, Peter A Merkel, et al.
Pageof 34